New Messaging: CDC Recommendation on Pediatric RSV Antibody Treatment

On August 3rd, the CDC announced the recommended use of nirsevimab (Beyfortus). Beyfortus is a new Respiratory Syncytial Virus (RSV) monoclonal antibody treatment for infants and young children at risk of severe illness caused by RSV infection. Beyfortus has been shown to reduce the risk of both hospitalizations and healthcare visits for RSV in infants by about 80% and is expected to be available this fall–when RSV season begins.

To help you answer questions from your community, the Public Health Communication Collaborative (PHCC) updated their Answers to Tough Questions to reflect the CDC’s latest recommendations.